Eupraxia Current Ratio from 2010 to 2026
| EPRX Stock | 8.28 0.07 0.84% |
Current Ratio | First Reported 2010-12-31 | Previous Quarter 6.95 | Current Value 3.58 | Quarterly Volatility 3.64336734 |
Check Eupraxia Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Eupraxia Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 161.5 K, Interest Expense of 1 M or Selling General Administrative of 19 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.79. Eupraxia financial statements analysis is a perfect complement when working with Eupraxia Pharmaceuticals Valuation or Volatility modules.
Eupraxia | Current Ratio | Build AI portfolio with Eupraxia Stock |
The evolution of Current Ratio for Eupraxia Pharmaceuticals Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Eupraxia Pharmaceuticals compares to historical norms and industry peers.
Latest Eupraxia Pharmaceuticals' Current Ratio Growth Pattern
Below is the plot of the Current Ratio of Eupraxia Pharmaceuticals Common over the last few years. It is a liquidity ratio that measures a company's ability to pay short-term obligations or those due within one year. It compares a firm's current assets to its current liabilities. Eupraxia Pharmaceuticals' Current Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Eupraxia Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 0.00 X | 10 Years Trend |
|
Current Ratio |
| Timeline |
Eupraxia Current Ratio Regression Statistics
| Arithmetic Mean | 5.78 | |
| Geometric Mean | 2.99 | |
| Coefficient Of Variation | 63.00 | |
| Mean Deviation | 2.85 | |
| Median | 7.42 | |
| Standard Deviation | 3.64 | |
| Sample Variance | 13.27 | |
| Range | 13.4435 | |
| R-Value | (0.25) | |
| Mean Square Error | 13.25 | |
| R-Squared | 0.06 | |
| Significance | 0.33 | |
| Slope | (0.18) | |
| Total Sum of Squares | 212.39 |
Eupraxia Current Ratio History
About Eupraxia Pharmaceuticals Financial Statements
Eupraxia Pharmaceuticals investors use historical fundamental indicators, such as Eupraxia Pharmaceuticals' Current Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Eupraxia Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 6.95 | 3.58 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Eupraxia Stock Analysis
When running Eupraxia Pharmaceuticals' price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.